Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. (1st June 2020)

• Record Type: Journal Article
• Authors: O'Sullivan, Leanne R.; Meade‐Murphy, Gerardene; Gilligan, Oonagh M.; Mykytiv, Vitaliy; Young, Paul W.; Cahill, Mary R.
• Is Part Of: British journal of haematology. Volume 192:Number 2(2021)
• Page Start: 322
• Page End: 332
• Publication Date: 2020-06-01
• Subjects: monoclonal gammopathy of undetermined significance -- multiple myeloma -- myeloma -- venous thromboembolism -- platelet hyperactivation -- platelet responsiveness; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16774
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Thrombotic events are common in patients with multiple myeloma (MM), smouldering myeloma (SM) and monoclonal gammopathy of undetermined significance (MGUS). Previous studies have indicated platelet hyperactivation as a feature of thrombotic risk in MM, but there is a dearth of data in MGUS. In the present study, multiparameter analysis of platelet activation and responsiveness was investigated by flow cytometry in patients with MGUS, SM/MM and healthy controls (HCs). The median platelet surface CD63 levels, annexin V and PAC‐1 antibody (specific for activated integrin αIIbβ3) binding were significantly elevated in patients with MGUS versus the HCs. These markers were also elevated in SM/MM, but not significantly. In all, 74% of MGUS and 38% of SM/MM patients had one or more elevated marker of platelet activation, compared to 19% of the HCs. Marker‐specific hyporesponsiveness of platelets to agonist [adenosine diphosphate (ADP), thrombin receptor‐activating peptide 6] stimulation in vitro was observed, with significantly reduced surface levels of P‐selectin in response to ADP in patients with MGUS. Platelet‐leucocyte aggregates were not altered in patients, while platelet‐associated immunoglobulins were elevated in a subset of patients. Overall, we found that platelet hyperactivation is prevalent in both MGUS and SM/MM patients and is potentially related to hyporesponsiveness. These observations suggest that further investigation of the predictive and prognostic value of platelet hyperactivation in such patients is warranted.